Litifilimab Delivers Sustained Skin Clearance in Cutaneous Lupus Through 52 Weeks

Clear or almost clear erythema rates nearly doubled in the placebo crossover group — from 4.2% at week 24 to 33.7% at week 52 — according to 52-week data from the phase 2 portion of the AMETHYST trial, presented at ACR Convergence 2026 in Orlando, Florida. That jump, within 28 weeks of starting active therapy, anchors the case for litifilimab in cutaneous lupus erythematosus (CLE). And it isn't the only number moving in the right direction.

Joseph Merola, MD, and colleagues reported continued improvement in skin erythema and other morphological features among patients on subcutaneous litifilimab, a monoclonal antibody that targets blood dendritic cell antigen 2 (BDCA2). The trial met its primary endpoint, and responses kept building well past the placebo-controlled window. For a disease that scars and discolors skin for life, durability matters as much as speed.

What is litifilimab, and why does CLE need it?

CLE is a chronic autoimmune disease. Inflammatory skin lesions can cause permanent scarring, dyspigmentation, alopecia, and disfigurement. Visible lesions that persist despite treatment take a heavy toll on quality of life.

Litifilimab binds BDCA2, a receptor on plasmacytoid dendritic cells. Blocking it suppresses production of proinflammatory cytokines and chemokines, including type I interferons, which drive lupus pathogenesis. The takeaway: the drug aims at a defined upstream mechanism, not broad immunosuppression.

How was the study designed?

AMETHYST (NCT05531565) is a randomized, double-blind, placebo-controlled, operationally seamless phase 2/3 trial. It evaluates subcutaneous litifilimab in patients with active chronic and/or subacute CLE, with or without systemic manifestations.

The phase 2 portion randomized and treated 93 participants. Key baseline details:

• All had moderate-to-severe erythema — a CLA-IGA-R erythema score of at least 3.
• Mean baseline CLASI-A score was 19.9, indicating substantial inflammatory activity.
• During the first 24 weeks, participants received litifilimab or placebo every 4 weeks.
• At week 24, placebo patients crossed over to active drug; everyone continued through week 52.

The primary endpoint measured the proportion achieving a CLA-IGA-R erythema score of 0 or 1 — clear or almost clear skin — at week 16. Secondary endpoints covered CLA-IGA-R erythema and other morphological characteristic (OMC) scores at week 24. Exploratory endpoints used the Clinician's Global Assessment of Skin (CGA-Skin) and Subject Global Assessment of Skin (SGA-Skin).

What did the 52-week data show?

Among patients on litifilimab throughout, clear or almost clear erythema rates rose from 19.0% at week 24 to 27.2% at week 52. The proportion achieving an OMC score of 0 climbed from 14.2% to 20.8%. In short, responses deepened with more time on drug.

The crossover group told an even starker story. Clear or almost clear erythema response rose from 4.2% at week 24 to 33.7% at week 52. OMC score-0 rates went from 0% to 27.5%. Responses appeared as early as 4 weeks after starting active treatment.

Clinician and patient assessments tracked the objective measures. At week 24, 55.6% of litifilimab-treated participants were rated moderately or substantially improved on CGA-Skin, versus 28.0% on placebo. In the crossover group, clinician-rated improvement jumped from 28.0% at week 24 to 72.7% at week 52. Patient-reported improvement in that group rose from 29.6% to 75.0% — three of four patients seeing their skin the way their doctors did. Continuous litifilimab recipients also kept improving on both assessments through week 52.

What are the caveats?

The investigators themselves flagged the limits. After week 24, all participants received active drug, so the extended period had no concurrent placebo comparison. The clinician- and patient-reported outcomes were exploratory. And the abstract did not detail adverse events from the 52-week analysis.

Larger confirmatory studies and comprehensive safety assessments will be needed to define the long-term benefit-risk profile. In plain words: the signal is strong, but the safety book isn't closed.

For dermatologists managing persistent CLE, where goals extend beyond calming inflammation to preventing irreversible skin damage, the AMETHYST data add weight to BDCA2 inhibition as a targeted strategy. As development continues, litifilimab could offer a new option for patients with active cutaneous lupus who need better control of inflammatory skin manifestations.